Why Ventyx Biosciences Stock Fell After-Hours

Ventyx Biosciences, Inc. (NASDAQ:VTYX) shares plunged in Monday's after-hours session after the company announced results from the Phase 2 trial of VTX002 in patients with moderate-to-severely active ulcerative colitis.

What To Know: The Phase 2 trial of VTX002 was a 13-week, randomized, double-blind, placebo-controlled, dose-ranging trial evaluating the efficacy and safety of two oral doses of VTX002 (30 mg and 60 mg once daily) in patients with moderate-to-severely active ulcerative colitis.

"The positive Phase 2 data for VTX002 establish a highly attractive profile for an oral agent in moderate-to-severely active UC, with the 60 mg dose achieving a compelling clinical remission rate, an unprecedented rate of complete endoscopic remission, and an excellent safety and tolerability profile," said William Sandborn, President and CMO. "I would like to thank all of the patients and investigators for their participation in this trial."

VTYX Price Action: Shares of VTYX were down 19.9% at $24.02 in the after-hours session at the time of publication, according to Benzinga Pro.

Image by Jan from Pixabay

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.